{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:04:16Z","timestamp":1787313856837,"version":"build-2736575974"},"reference-count":293,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["Ha7431\/3-1"],"award-info":[{"award-number":["Ha7431\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SFB\/TRR 296"],"award-info":[{"award-number":["SFB\/TRR 296"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SFB1382, Project-ID 403224013"],"award-info":[{"award-number":["SFB1382, Project-ID 403224013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["Ta434\/8-1"],"award-info":[{"award-number":["Ta434\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","award":["2021_EKEA.145"],"award-info":[{"award-number":["2021_EKEA.145"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Primary liver cancer, represented mainly by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), is one of the most common and deadliest tumors worldwide. While surgical resection or liver transplantation are the best option in early disease stages, these tumors often present in advanced stages and systemic treatment is required to improve survival time. The emergence of immune checkpoint inhibitor (ICI) therapy has had a positive impact especially on the treatment of advanced cancers, thereby establishing immunotherapy as part of first-line treatment in HCC and CCA. Nevertheless, low response rates reflect on the usually cold or immunosuppressed tumor microenvironment of primary liver cancer. In this review, we aim to summarize mechanisms of resistance leading to tumor immune escape with a special focus on the composition of tumor microenvironment in both HCC and CCA, also reflecting on recent important developments in ICI combination therapy. Furthermore, we discuss how combination of ICIs with established primary liver cancer treatments (e.g. multikinase inhibitors and chemotherapy) as well as more complex combinations with state-of-the-art therapeutic concepts may reshape the tumor microenvironment, leading to higher response rates and long-lasting antitumor immunity for primary liver cancer patients.<\/jats:p>","DOI":"10.1055\/a-2334-8311","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T19:17:16Z","timestamp":1716923836000},"page":"159-179","source":"Crossref","is-referenced-by-count":12,"title":["Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?"],"prefix":"10.1055","volume":"44","author":[{"given":"Wiebke","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kuzminskaya","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Lurje","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hammerich","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"H Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"M Arnold","year":"2020","journal-title":"Gastroenterology"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3390\/ijms20061465","article-title":"Treatment strategies for hepatocellular carcinoma \u2013 a multidisciplinary approach","volume":"20","author":"I Lurje","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"S 01","key":"ref5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"A Forner","year":"2019","journal-title":"Liver Int"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"J Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"G K Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"A X Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"S Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"A Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7340","key":"ref14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"H Ledford","year":"2011","journal-title":"Nature"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2011.09.018","article-title":"The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use","volume":"48","author":"Z Hanaizi","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref16","first-page":"180","article-title":"Opdivo (nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"L A Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"J Sul","year":"2016","journal-title":"Oncologist"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"A B El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"A X Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"T Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial","volume":"38","author":"R S Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5022","key":"ref22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","article-title":"Cancer; a biological approach. I. The processes of control","volume":"1","author":"M Burnet","year":"1957","journal-title":"BMJ"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"G P Dunn","year":"2002","journal-title":"Nat Immunol"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer-natural killer cell immunity cycle","volume":"20","author":"N D Huntington","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","article-title":"CD4+ T cells in cancer","volume":"4","author":"D E Speiser","year":"2023","journal-title":"Nat Cancer"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"D S Chen","year":"2013","journal-title":"Immunity"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.autrev.2019.02.006","article-title":"Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy","volume":"18","author":"S C Funes","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/17588359221096219","article-title":"Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle","volume":"14","author":"A M Starzer","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"S C Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"M Z Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2004.06.017","article-title":"B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse","volume":"21","author":"T Pentcheva-Hoang","year":"2004","journal-title":"Immunity"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"993581","DOI":"10.3389\/fams.2022.993581","article-title":"Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach","volume":"8","author":"I Azarov","year":"2022","journal-title":"Front Appl Math Stat"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"N Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000503254","article-title":"Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1\/PD-L1 and anti-CTLA-4 antibodies","volume":"8","author":"M Kudo","year":"2019","journal-title":"Liver Cancer"},{"issue":"18","key":"ref35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"V A Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"101480","DOI":"10.1016\/j.smim.2021.101480","article-title":"Emerging concepts in PD-1 checkpoint biology","volume":"52","author":"K E Pauken","year":"2021","journal-title":"Semin Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","article-title":"PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"J Liu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/cancers15102718","article-title":"Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment","volume":"15","author":"D C Ziogas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"17","key":"ref39","doi-asserted-by":"crossref","first-page":"9958","DOI":"10.3390\/ijms23179958","article-title":"LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors","volume":"23","author":"N Sauer","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Y Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","article-title":"TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors","volume":"72","author":"N Sauer","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.02.009","article-title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"167","author":"M Kudo","year":"2022","journal-title":"Eur J Cancer"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000529636","article-title":"Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the Phase 3 KEYNOTE-240 trial","volume":"12","author":"P Merle","year":"2023","journal-title":"Liver Cancer"},{"issue":"07","key":"ref45","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, Phase III trial","volume":"41","author":"S Qin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study","volume":"38","author":"A Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"M Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"P Sharma","year":"2017","journal-title":"Cell"},{"issue":"10","key":"ref49","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"I Mellman","year":"2023","journal-title":"Immunity"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"J Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/0008-5472.CAN-08-2654","article-title":"Coordination of intratumoral immune reaction and human colorectal cancer recurrence","volume":"69","author":"M Camus","year":"2009","journal-title":"Cancer Res"},{"issue":"670","key":"ref52","doi-asserted-by":"crossref","first-page":"eabo3605","DOI":"10.1126\/scitranslmed.abo3605","article-title":"Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment","volume":"14","author":"N Kirchhammer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"S Maleki Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"04","key":"ref54","doi-asserted-by":"crossref","first-page":"e006401","DOI":"10.1136\/jitc-2022-006401","article-title":"Barriers to immune cell infiltration in tumors","volume":"11","author":"M M Melssen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"216038","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Z Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1043667","DOI":"10.3389\/fimmu.2022.1043667","article-title":"Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition","volume":"13","author":"S Tao","year":"2023","journal-title":"Front Immunol"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0043-1776127","article-title":"Unraveling the complexities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"43","author":"X Han","year":"2023","journal-title":"Semin Liver Dis"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"672356","DOI":"10.3389\/fimmu.2021.672356","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12","author":"Z Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"P Bonaventura","year":"2019","journal-title":"Front Immunol"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"D L Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"R M Samstein","year":"2019","journal-title":"Nat Genet"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"T A Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"D J McGrail","year":"2021","journal-title":"Ann Oncol"},{"issue":"04","key":"ref64","doi-asserted-by":"crossref","first-page":"HEP39","DOI":"10.2217\/hep-2020-0034","article-title":"Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma","volume":"8","author":"M Wong","year":"2021","journal-title":"Hepat Oncol"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.21037\/jgo-21-776","article-title":"Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma","volume":"12","author":"Y Zheng","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/liv.14706","article-title":"Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma","volume":"41","author":"C N Wong","year":"2021","journal-title":"Liver Int"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-024-03257-7","article-title":"Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma","volume":"22","author":"X Yang","year":"2024","journal-title":"BMC Med"},{"issue":"08","key":"ref68","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3390\/cancers15082379","article-title":"Non-inflamed tumor microenvironment and methylation\/downregulation of antigen-presenting machineries in cholangiocarcinoma","volume":"15","author":"N Nishida","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"ref69","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.trecan.2021.07.006","article-title":"HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy","volume":"7","author":"L Maggs","year":"2021","journal-title":"Trends Cancer"},{"issue":"05","key":"ref70","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"A Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"issue":"19","key":"ref71","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.3390\/ijms21197378","article-title":"Dendritic cell and T cell crosstalk in liver fibrogenesis and hepatocarcinogenesis: implications for prevention and therapy of liver cancer","volume":"21","author":"I Lurje","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2147\/JHC.S336858","article-title":"Wnt\/\u03b2-catenin signaling as a driver of hepatocellular carcinoma progression: an emphasis on molecular pathways","volume":"8","author":"M Deldar Abad Paskeh","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"issue":"15","key":"ref73","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1073\/pnas.95.15.8847","article-title":"Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas","volume":"95","author":"A de La Coste","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"J J Harding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","article-title":"WNT\/\u03b2-catenin regulatory roles on PD-(L)1 and immunotherapy responses","volume":"24","author":"K Mortezaee","year":"2024","journal-title":"Clin Exp Med"},{"issue":"16","key":"ref76","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.3390\/cancers13164202","article-title":"Exploring the interplay of telomerase reverse transcriptase and \u03b2-catenin in hepatocellular carcinoma","volume":"13","author":"S Kotiyal","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical Wnt signalling is required for TGF-\u03b2-mediated fibrosis","volume":"3","author":"A Akhmetshina","year":"2012","journal-title":"Nat Commun"},{"issue":"11","key":"ref78","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.molmed.2019.06.007","article-title":"Immunomodulatory TGF-\u03b2 signaling in hepatocellular carcinoma","volume":"25","author":"J Chen","year":"2019","journal-title":"Trends Mol Med"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3892\/ol.2021.12464","article-title":"Tumor \u03b2-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden","volume":"21","author":"S Muto","year":"2021","journal-title":"Oncol Lett"},{"issue":"08","key":"ref80","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"M Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"issue":"08","key":"ref81","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"A X Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3892\/ol.2022.13337","article-title":"Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT\/\u03b2-catenin signal activation","volume":"24","author":"A Kuwano","year":"2022","journal-title":"Oncol Lett"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1538-7445.AM2022-2145","article-title":"Abstract 2145: genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial","volume":"82","author":"J Neely","year":"2022","journal-title":"Cancer Res"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"C Montironi","year":"2023","journal-title":"Gut"},{"issue":"03","key":"ref85","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/biom12030453","article-title":"Cross-talk between p53 and Wnt signaling in cancer","volume":"12","author":"Q Xiao","year":"2022","journal-title":"Biomolecules"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"W Peng","year":"2016","journal-title":"Cancer Discov"},{"issue":"03","key":"ref87","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.3390\/ijms24032652","article-title":"The role of PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma metabolism","volume":"24","author":"L-Y Tian","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"06","key":"ref88","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s13277-013-0945-2","article-title":"Increased activation of PI3K\/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K\/mTOR inhibition presents a possible therapeutic strategy","volume":"34","author":"S Yothaisong","year":"2013","journal-title":"Tumour Biol"},{"issue":"11","key":"ref89","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41419-022-05411-6","article-title":"MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities","volume":"13","author":"C Sequera","year":"2022","journal-title":"Cell Death Dis"},{"issue":"04","key":"ref90","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/0008-5472.CAN-22-0232","article-title":"MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages","volume":"83","author":"R Dhanasekaran","year":"2023","journal-title":"Cancer Res"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.32182","article-title":"MicroRNA-206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c-Myc mice","volume":"76","author":"N Liu","year":"2022","journal-title":"Hepatology"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12964-023-01130-3","article-title":"KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion","volume":"21","author":"H Sabe","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"04","key":"ref93","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"M A Martin-Serrano","year":"2023","journal-title":"Gut"},{"issue":"20","key":"ref94","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.4161\/15384101.2014.965054","article-title":"IDH mutations in liver cell plasticity and biliary cancer","volume":"13","author":"S K Saha","year":"2014","journal-title":"Cell Cycle"},{"issue":"03","key":"ref95","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH inhibits IFN\u03b3-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"M J Wu","year":"2022","journal-title":"Cancer Discov"},{"issue":"04","key":"ref96","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/ijms21041266","article-title":"Activation of mTOR signaling pathway in hepatocellular carcinoma","volume":"21","author":"G Ferr\u00edn","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"260","key":"ref97","first-page":"tr8","article-title":"The Jak-STAT pathway stimulated by interferon gamma","volume":"2004","author":"C M Horvath","year":"2004","journal-title":"Sci STKE"},{"issue":"01","key":"ref98","doi-asserted-by":"crossref","first-page":"HEP18","DOI":"10.2217\/hep-2020-0001","article-title":"JAK\/STAT signaling in hepatocellular carcinoma","volume":"7","author":"J J Hin Tang","year":"2020","journal-title":"Hepat Oncol"},{"issue":"07","key":"ref99","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"D AA Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"01","key":"ref100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"D Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"05","key":"ref101","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jhep.2012.12.015","article-title":"The functional impairment of HCC-infiltrating \u03b3\u03b4 T cells, partially mediated by regulatory T cells in a TGF\u03b2- and IL-10-dependent manner","volume":"58","author":"Y Yi","year":"2013","journal-title":"J Hepatol"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40659-015-0016-9","article-title":"TGF-\u03b21 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma","volume":"48","author":"Y Chen","year":"2015","journal-title":"Biol Res"},{"issue":"12","key":"ref103","doi-asserted-by":"crossref","first-page":"100900","DOI":"10.1016\/j.jhepr.2023.100900","article-title":"TGF\u03b2-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p","volume":"5","author":"C Louis","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"21","key":"ref104","doi-asserted-by":"crossref","first-page":"34387","DOI":"10.18632\/oncotarget.16166","article-title":"High TGF-\u03b21 expression predicts poor disease prognosis in hepatocellular carcinoma patients","volume":"8","author":"L Peng","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"ref105","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.3390\/ijms21103599","article-title":"Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers","volume":"21","author":"H X Lim","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Y Wu","year":"2022","journal-title":"Mol Cancer"},{"issue":"06","key":"ref107","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"D-M Kuang","year":"2009","journal-title":"J Exp Med"},{"issue":"01","key":"ref108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12672-023-00681-8","article-title":"The role of myeloid-derived suppressor cells in liver cancer","volume":"14","author":"S Zhou","year":"2023","journal-title":"Discov Oncol"},{"issue":"12","key":"ref109","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","article-title":"Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment","volume":"21","author":"Y Lin","year":"2019","journal-title":"Neoplasia"},{"issue":"01","key":"ref110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.32099","article-title":"CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase","volume":"75","author":"Y Lin","year":"2022","journal-title":"Hepatology"},{"issue":"03","key":"ref111","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-20-0431","article-title":"IL1\u03b2 promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D","volume":"9","author":"M Kiss","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"ref112","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/cancers12123826","article-title":"Impact of angiogenesis- and hypoxia-associated polymorphisms on tumor recurrence in patients with hepatocellular carcinoma undergoing surgical resection","volume":"12","author":"H Miller","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"02","key":"ref113","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000521613","article-title":"Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma","volume":"11","author":"I Lurje","year":"2022","journal-title":"Liver Cancer"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1038\/s41598-023-39487-7","article-title":"Genetic polymorphisms in interleukin-1\u03b2 (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma","volume":"13","author":"I Lurje","year":"2023","journal-title":"Sci Rep"},{"issue":"10","key":"ref115","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"L Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"ref116","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"A Mantovani","year":"2004","journal-title":"Trends Immunol"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"173090","DOI":"10.1016\/j.ejphar.2020.173090","article-title":"Macrophage M1\/M2 polarization","volume":"877","author":"C Yunna","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"1129831","DOI":"10.3389\/fmolb.2023.1129831","article-title":"The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities","volume":"10","author":"M S Kohlhepp","year":"2023","journal-title":"Front Mol Biosci"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Y Pan","year":"2020","journal-title":"Front Immunol"},{"issue":"17","key":"ref120","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","article-title":"Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin","volume":"186","author":"B Ruf","year":"2023","journal-title":"Cell"},{"issue":"08","key":"ref121","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1349-7006.2010.01614.x","article-title":"Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma","volume":"101","author":"H Hasita","year":"2010","journal-title":"Cancer Sci"},{"issue":"02","key":"ref122","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/15384101.2014.977112","article-title":"miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression","volume":"14","author":"X Sun","year":"2015","journal-title":"Cell Cycle"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","article-title":"The role of STAT3 in leading the crosstalk between human cancers and the immune system","volume":"415","author":"Y Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"107986","DOI":"10.1016\/j.pharmthera.2021.107986","article-title":"Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: a TAM-pting approach","volume":"231","author":"A N Chamseddine","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"08","key":"ref125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2468-1253(23)00111-5","article-title":"Fibroblasts in liver cancer: functions and therapeutic translation","volume":"8","author":"S Affo","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"I Mederacke","year":"2013","journal-title":"Nat Commun"},{"issue":"09","key":"ref127","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41417-021-00343-3","article-title":"Correction: cancer-associated fibroblasts: overview, progress, challenges, and directions","volume":"28","author":"Q Ping","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"X Mao","year":"2021","journal-title":"Mol Cancer"},{"issue":"06","key":"ref129","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"S Affo","year":"2021","journal-title":"Cancer Cell"},{"issue":"7931","key":"ref130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"A Filliol","year":"2022","journal-title":"Nature"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"S Koyama","year":"2016","journal-title":"Nat Commun"},{"issue":"20","key":"ref132","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.3390\/cancers15204943","article-title":"TIM-3 expression and M2 polarization of macrophages in the TGF\u03b2-activated tumor microenvironment in colorectal cancer","volume":"15","author":"M Katagata","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"04","key":"ref133","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"S-R Woo","year":"2012","journal-title":"Cancer Res"},{"issue":"01","key":"ref134","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12967-020-02469-8","article-title":"Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis","volume":"18","author":"M Guo","year":"2020","journal-title":"J Transl Med"},{"issue":"10","key":"ref135","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","article-title":"Tim-3 fosters HCC development by enhancing TGF-\u03b2-mediated alternative activation of macrophages","volume":"64","author":"W Yan","year":"2015","journal-title":"Gut"},{"issue":"11","key":"ref136","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut-liver axis and gut microbiota in health and liver disease","volume":"21","author":"C L Hsu","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.semcancer.2022.01.005","article-title":"Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data","volume":"86","author":"U Harkus","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"01","key":"ref138","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Y Wen","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"02","key":"ref139","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4049\/jimmunol.172.2.1009","article-title":"Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition","volume":"172","author":"V G Pillarisetty","year":"2004","journal-title":"J Immunol"},{"issue":"01","key":"ref140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"J M Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"101191","DOI":"10.1016\/j.mam.2023.101191","article-title":"Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies","volume":"92","author":"I Lurje","year":"2023","journal-title":"Mol Aspects Med"},{"issue":"06","key":"ref142","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma","volume":"32","author":"M M Kirstein","year":"2016","journal-title":"Visc Med"},{"issue":"03","key":"ref143","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"V W Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"04","key":"ref144","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"G Targher","year":"2024","journal-title":"Gut"},{"issue":"01","key":"ref145","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"M E Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"03","key":"ref146","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"J M Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"01","key":"ref147","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"M Pinter","year":"2021","journal-title":"Gut"},{"issue":"05","key":"ref148","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1053\/j.gastro.2023.04.014","article-title":"Atezolizumab plus bevacizumab in advanced HCC: efficacy in NASH-specific etiology","volume":"165","author":"J M Llovet","year":"2023","journal-title":"Gastroenterology"},{"issue":"08","key":"ref149","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"J M Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"01","key":"ref150","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1038\/s41467-021-24734-0","article-title":"CD8+ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells","volume":"12","author":"Y Koda","year":"2021","journal-title":"Nat Commun"},{"issue":"7854","key":"ref151","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"M Dudek","year":"2021","journal-title":"Nature"},{"issue":"02","key":"ref152","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","article-title":"Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling","volume":"79","author":"E Kotsiliti","year":"2023","journal-title":"J Hepatol"},{"issue":"7593","key":"ref153","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"C Ma","year":"2016","journal-title":"Nature"},{"issue":"04","key":"ref154","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"O Krenkel","year":"2018","journal-title":"Hepatology"},{"issue":"03","key":"ref155","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/gutjnl-2019-318382","article-title":"Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis","volume":"69","author":"O Krenkel","year":"2020","journal-title":"Gut"},{"issue":"06","key":"ref156","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","article-title":"XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis","volume":"27","author":"A Deczkowska","year":"2021","journal-title":"Nat Med"},{"issue":"02","key":"ref157","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","volume":"185","author":"M Guilliams","year":"2022","journal-title":"Cell"},{"issue":"01","key":"ref158","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/HEP.0000000000000270","article-title":"Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression","volume":"78","author":"A Guillot","year":"2023","journal-title":"Hepatology"},{"issue":"05","key":"ref159","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2013preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"J Weber","year":"2010","journal-title":"Semin Oncol"},{"issue":"7854","key":"ref160","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"D Pfister","year":"2021","journal-title":"Nature"},{"issue":"03","key":"ref161","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","article-title":"Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD","volume":"77","author":"S Wabitsch","year":"2022","journal-title":"J Hepatol"},{"issue":"01","key":"ref162","doi-asserted-by":"crossref","first-page":"10807","DOI":"10.1038\/s41598-023-37736-3","article-title":"Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer","volume":"13","author":"M Inomata","year":"2023","journal-title":"Sci Rep"},{"issue":"02","key":"ref163","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"T Meyer","year":"2023","journal-title":"J Hepatol"},{"issue":"01","key":"ref164","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.gastro.2023.02.042","article-title":"Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150","volume":"165","author":"M Espinoza","year":"2023","journal-title":"Gastroenterology"},{"issue":"11","key":"ref165","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/apt.17441","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort","volume":"57","author":"F Jost-Brinkmann","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref166","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Z Wang","year":"2019","journal-title":"Nat Med"},{"issue":"07","key":"ref167","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","article-title":"Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity","volume":"183","author":"A E Ringel","year":"2020","journal-title":"Cell"},{"issue":"04","key":"ref168","doi-asserted-by":"crossref","first-page":"100185","DOI":"10.1016\/j.esmoop.2021.100185","article-title":"Cancer and hepatic steatosis","volume":"6","author":"R Paternostro","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"ref169","first-page":"9","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"J Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"1247614","DOI":"10.3389\/fonc.2023.1247614","article-title":"Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review","volume":"13","author":"P Muscolino","year":"2023","journal-title":"Front Oncol"},{"issue":"06","key":"ref171","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.jhepr.2023.100747","article-title":"Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma","volume":"5","author":"D J Pinato","year":"2023","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"06","key":"ref172","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"M S Lee","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref173","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"S Qin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"02","key":"ref174","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"L Rimassa","year":"2023","journal-title":"J Hepatol"},{"issue":"02","key":"ref175","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/j.gastro.2020.03.074","article-title":"Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice","volume":"159","author":"D K Chiu","year":"2020","journal-title":"Gastroenterology"},{"issue":"08","key":"ref176","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"K S Peggs","year":"2009","journal-title":"J Exp Med"},{"issue":"21","key":"ref177","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"M A Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"02","key":"ref178","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"J D Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"02","key":"ref179","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"H J Lenz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"ref180","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"M D Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"ref181","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"T Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"09","key":"ref182","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/onco.13819","article-title":"FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib","volume":"26","author":"M T Saung","year":"2021","journal-title":"Oncologist"},{"issue":"08","key":"ref183","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/cts.13544","article-title":"Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)","volume":"16","author":"B Sangro","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"27","key":"ref184","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a Phase I\/II study","volume":"39","author":"R K Kelley","year":"2021","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref185","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"G K Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"09","key":"ref186","doi-asserted-by":"crossref","first-page":"e002794","DOI":"10.1136\/jitc-2021-002794","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma","volume":"9","author":"T F Greten","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"06","key":"ref187","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"A Vogel","year":"2021","journal-title":"Ann Oncol"},{"issue":"03","key":"ref188","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"M Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"09","key":"ref189","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a Phase 2 Nonrandomized Clinical Trial","volume":"6","author":"O Klein","year":"2020","journal-title":"JAMA Oncol"},{"issue":"06","key":"ref190","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"R D Kim","year":"2020","journal-title":"JAMA Oncol"},{"issue":"13","key":"ref191","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Y Doki","year":"2022","journal-title":"Cancer Med"},{"issue":"05","key":"ref192","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"D Hanahan","year":"2011","journal-title":"Cell"},{"issue":"03","key":"ref193","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","article-title":"The role of angiogenesis in hepatocellular carcinoma","volume":"25","author":"M A Morse","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"05","key":"ref194","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"K A Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"05","key":"ref195","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"M Kudo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"385","key":"ref196","doi-asserted-by":"crossref","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"E Allen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"12","key":"ref197","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"R J Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"09","key":"ref198","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"T K Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"ref199","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"R S Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"04","key":"ref200","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"A L Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"07","key":"ref201","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Z Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"S Qin","year":"2023","journal-title":"Lancet"},{"issue":"08","key":"ref203","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"R K Kelley","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref204","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"J M Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"S Qin","year":"2023","journal-title":"Lancet"},{"issue":"03","key":"ref206","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","article-title":"Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial","volume":"30","author":"H D Kim","year":"2024","journal-title":"Nat Med"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"777617","DOI":"10.3389\/fonc.2021.777617","article-title":"Recent advances in the mechanism research and clinical treatment of anti-angiogenesis in biliary tract cancer","volume":"11","author":"Y Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"04","key":"ref208","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma","volume":"9","author":"J Lin","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":". EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jinorgbio.2016.06.021","article-title":"Anticancer metal drugs and immunogenic cell death","volume":"165","author":"A Terenzi","year":"2016","journal-title":"J Inorg Biochem"},{"issue":"21","key":"ref211","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"A R de Biasi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"04","key":"ref212","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"A Tesniere","year":"2010","journal-title":"Oncogene"},{"issue":"18","key":"ref213","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"E Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"03","key":"ref214","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"S Job","year":"2020","journal-title":"Hepatology"},{"issue":"22","key":"ref215","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"L Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"ref216","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"P Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"08","key":"ref217","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"M Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"03","key":"ref218","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1093\/oncolo\/oyab073","article-title":"A Phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma","volume":"27","author":"C Monge","year":"2022","journal-title":"Oncologist"},{"issue":"19","key":"ref219","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.34394","article-title":"A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01","volume":"128","author":"V Sahai","year":"2022","journal-title":"Cancer"},{"issue":"06","key":"ref220","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"D Y Oh","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"08","key":"ref221","first-page":"EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"D Y Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"07","key":"ref222","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/imt-2022-0269","article-title":"TOPAZ-1: a new standard of care for advanced biliary tract cancers?","volume":"15","author":"M I Ebia","year":"2023","journal-title":"Immunotherapy"},{"key":"ref223","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"R K Kelley","year":"2023","journal-title":"Lancet"},{"issue":"13","key":"ref224","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies","volume":"15","author":"J H Lo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"04","key":"ref225","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"A J Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"ref226","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.3390\/curroncol30110711","article-title":"Advances in immunotherapy for hepatocellular carcinoma (HCC)","volume":"30","author":"F Bicer","year":"2023","journal-title":"Curr Oncol"},{"issue":"04","key":"ref227","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","article-title":"Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation?","volume":"26","author":"D Enrico","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"ref228","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1001\/jamaoncol.2022.4733","article-title":"Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma","volume":"8","author":"C Kim","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6230","key":"ref229","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"T N Schumacher","year":"2015","journal-title":"Science"},{"issue":"7749","key":"ref230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"R Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"09","key":"ref231","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"J M Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"04","key":"ref232","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"M Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"12","key":"ref233","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"S Gettinger","year":"2017","journal-title":"Cancer Discov"},{"issue":"02","key":"ref234","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"J Gao","year":"2016","journal-title":"Cell"},{"key":"ref235","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"A Sucker","year":"2017","journal-title":"Nat Commun"},{"issue":"7559","key":"ref236","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"S Spranger","year":"2015","journal-title":"Nature"},{"key":"ref237","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1038\/ncomms7072","article-title":"An IL-27\/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction","volume":"6","author":"C Zhu","year":"2015","journal-title":"Nat Commun"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"1112672","DOI":"10.3389\/fimmu.2023.1112672","article-title":"Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma","volume":"14","author":"C Yang","year":"2023","journal-title":"Front Immunol"},{"issue":"01","key":"ref239","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"\u00c1 de Mingo Pulido","year":"2018","journal-title":"Cancer Cell"},{"issue":"7865","key":"ref240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"K O Dixon","year":"2021","journal-title":"Nature"},{"issue":"03","key":"ref241","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2567.2004.02087.x","article-title":"LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors","volume":"114","author":"S Buisson","year":"2005","journal-title":"Immunology"},{"issue":"01","key":"ref242","doi-asserted-by":"crossref","first-page":"100620","DOI":"10.1016\/j.jhepr.2022.100620","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma","volume":"5","author":"B Scheiner","year":"2022","journal-title":"JHEP Rep Innov Hepatol"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"655697","DOI":"10.3389\/fimmu.2021.655697","article-title":"Hepatocellular carcinoma immune landscape and the potential of immunotherapies","volume":"12","author":"J Giraud","year":"2021","journal-title":"Front Immunol"},{"issue":"7637","key":"ref244","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"D S Chen","year":"2017","journal-title":"Nature"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fimmu.2020.00223","article-title":"Sensitizing the tumor microenvironment to immune checkpoint therapy","volume":"11","author":"R M Zemek","year":"2020","journal-title":"Front Immunol"},{"key":"ref246","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"L H Butterfield","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"03","key":"ref247","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"L Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"04","key":"ref248","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"G Kroemer","year":"2022","journal-title":"Nat Immunol"},{"issue":"04","key":"ref249","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543784.2022.2009455","article-title":"Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials","volume":"31","author":"A Di Federico","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"issue":"05","key":"ref250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"E A Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"11","key":"ref251","doi-asserted-by":"crossref","first-page":"e005457","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","volume":"10","author":"M de la Torre-Al\u00e1ez","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"01","key":"ref252","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"A Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"01","key":"ref253","doi-asserted-by":"crossref","first-page":"2219591","DOI":"10.1080\/2162402X.2023.2219591","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in oncology","volume":"12","author":"J Sprooten","year":"2023","journal-title":"OncoImmunology"},{"issue":"05","key":"ref254","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"J M Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref255","doi-asserted-by":"crossref","first-page":"LBA432","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA432","article-title":"EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization","volume":"42","author":"R Lencioni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"07","key":"ref256","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1080\/02656736.2018.1462535","article-title":"Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins","volume":"34","author":"M Ahmed","year":"2018","journal-title":"Int J Hyperthermia"},{"issue":"05","key":"ref257","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12192-011-0261-y","article-title":"Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation","volume":"16","author":"S P Haen","year":"2011","journal-title":"Cell Stress Chaperones"},{"issue":"10","key":"ref258","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"H Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"issue":"09","key":"ref259","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/cam4.2949","article-title":"Oncolytic virotherapy in hepato-bilio-pancreatic cancer: the key to breaking the log jam?","volume":"9","author":"Y Li","year":"2020","journal-title":"Cancer Med"},{"issue":"185","key":"ref260","first-page":"185ra63","article-title":"Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans","volume":"5","author":"M K Kim","year":"2013","journal-title":"Sci Transl Med"},{"issue":"03","key":"ref261","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"J Heo","year":"2013","journal-title":"Nat Med"},{"issue":"08","key":"ref262","doi-asserted-by":"crossref","first-page":"1615817","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"M Moehler","year":"2019","journal-title":"OncoImmunology"},{"key":"ref263","doi-asserted-by":"crossref","first-page":"650486","DOI":"10.3389\/fimmu.2021.650486","article-title":"In situ vaccination as a strategy to modulate the immune microenvironment of hepatocellular carcinoma","volume":"12","author":"I Lurje","year":"2021","journal-title":"Front Immunol"},{"issue":"01","key":"ref264","doi-asserted-by":"crossref","first-page":"1771143","DOI":"10.1080\/2162402X.2020.1771143","article-title":"Trial watch: TLR3 agonists in cancer therapy","volume":"9","author":"J Le Naour","year":"2020","journal-title":"OncoImmunology"},{"issue":"7549","key":"ref265","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nature14138","article-title":"Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9","volume":"520","author":"U Ohto","year":"2015","journal-title":"Nature"},{"key":"ref266","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/JHC.S301375","article-title":"The combination immunotherapy of TLR9 agonist and OX40 agonist via intratumoural injection for hepatocellular carcinoma","volume":"8","author":"Z Zhou","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"issue":"12","key":"ref267","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"K T Byrne","year":"2016","journal-title":"Cell Rep"},{"issue":"05","key":"ref268","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"L P Diggs","year":"2021","journal-title":"J Hepatol"},{"issue":"09","key":"ref269","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"W S Lee","year":"2020","journal-title":"Exp Mol Med"},{"issue":"02","key":"ref270","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"V Chew","year":"2019","journal-title":"Gut"},{"issue":"04","key":"ref271","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Y Liu","year":"2023","journal-title":"J Hepatol"},{"key":"ref272","doi-asserted-by":"crossref","first-page":"1151373","DOI":"10.3389\/fonc.2023.1151373","article-title":"The origins, roles and therapies of cancer associated fibroblast in liver cancer","volume":"13","author":"N Zulaziz","year":"2023","journal-title":"Front Oncol"},{"issue":"50","key":"ref273","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"C Feig","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7693","key":"ref274","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"S Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"07","key":"ref275","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"S I Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"05","key":"ref276","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Y Chen","year":"2015","journal-title":"Hepatology"},{"issue":"01","key":"ref277","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"J Tan","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"ref278","doi-asserted-by":"crossref","first-page":"101256","DOI":"10.1016\/j.xcrm.2023.101256","article-title":"FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis","volume":"4","author":"P R\u00e9gnier","year":"2023","journal-title":"Cell Rep Med"},{"issue":"04","key":"ref279","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/acsnano.0c00708","article-title":"Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma","volume":"14","author":"Z Yu","year":"2020","journal-title":"ACS Nano"},{"issue":"09","key":"ref280","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/gutjnl-2022-327909","article-title":"Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade","volume":"72","author":"C Conche","year":"2023","journal-title":"Gut"},{"issue":"10","key":"ref281","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","article-title":"CXCR2 inhibition enables NASH-HCC immunotherapy","volume":"71","author":"J Leslie","year":"2022","journal-title":"Gut"},{"key":"ref282","doi-asserted-by":"crossref","first-page":"TPS631","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS631","article-title":"A phase I\/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC)","volume":"41","author":"T RJ Evans","year":"2023","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref283","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","article-title":"Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade","volume":"68","author":"Y Zhu","year":"2019","journal-title":"Gut"},{"issue":"10","key":"ref284","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"E Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"issue":"10","key":"ref285","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"R J Akhurst","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"03","key":"ref286","first-page":"758","article-title":"Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced\/metastatic biliary tract cancers","volume":"78","author":"C Yoo","year":"2023","journal-title":"Hepatology"},{"issue":"30","key":"ref287","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2217\/fon-2023-0491","article-title":"TGF-\u03b2: the apex predator of immune checkpoints","volume":"19","author":"B Oronsky","year":"2023","journal-title":"Future Oncol"},{"issue":"01","key":"ref288","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"H A Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"08","key":"ref289","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"J J Harding","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"23","key":"ref290","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1158\/1078-0432.CCR-21-0261","article-title":"Safety and antitumor activity of \u03b1-PD-L1 antibody as monotherapy or in combination with \u03b1-TIM-3 antibody in patients with microsatellite instability-high\/mismatch repair-deficient tumors","volume":"27","author":"A Hollebecque","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"09","key":"ref291","doi-asserted-by":"crossref","first-page":"djx146","DOI":"10.1093\/jnci\/djx146","article-title":"Two-by-two factorial cancer treatment trials: is sufficient attention being paid to possible interactions?","volume":"109","author":"B Freidlin","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"05","key":"ref292","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41571-023-00731-8","article-title":"Exploring a new pathway for biomarker-based approval of immunotherapies","volume":"20","author":"J M Llovet","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"ref293","doi-asserted-by":"crossref","first-page":"215853","DOI":"10.1016\/j.canlet.2022.215853","article-title":"Immunotherapy of cholangiocarcinoma: therapeutic strategies and predictive biomarkers","volume":"546","author":"R Chen","year":"2022","journal-title":"Cancer Lett"},{"issue":"06","key":"ref294","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"A Magen","year":"2023","journal-title":"Nat Med"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2334-8311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T05:49:05Z","timestamp":1730785745000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2334-8311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":293,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,7,12]]},"published-print":{"date-parts":[[2024,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2334-8311","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,28]]},"published":{"date-parts":[[2024,5]]}}}